| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | etb |
| Uniprot No | P09332 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 32-277aa |
| 氨基酸序列 | KEYSAEEIRKLKQKFEVPPTDKELYTHITDNARSPYNSVGTVFVKGSTLATGVLIGKNTIVTNYHVAREAAKNPSNIIFTPAQNRDAEKNEFPTPYGKFEAEEIKESPYGQGLDLAIIKLKPNEKGESAGDLIQPANIPDHIDIQKGDKYSLLGYPYNYSAYSLYQSQIEMFNDSQYFGYTEVGNSGSGIFNLKGELIGIHSGKGGQHNLPIGVFFNRKISSLYSVDNTFGDTLGNDLKKRAKLDK |
| 预测分子量 | 34.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ETB重组蛋白的3篇参考文献及其摘要概括：
1. **《Cloning and expression of human endothelin-converting enzyme (ECE-1) cDNA and its functional characterization》**
- **作者**: Shimada K, Hosoda Y, et al.
- **摘要**: 研究通过克隆和表达人源内皮素转化酶(ECE-1)的cDNA，验证其在体外对内皮素前体的水解活性，并分析ETB受体结合特性，为研究ETB相关信号通路提供基础。
2. **《Endothelin B receptor signaling in cancer progression》**
- **作者**: Bagnato A, Rosanò L.
- **摘要**: 探讨ETB受体在肿瘤血管生成和转移中的作用，通过重组ETB蛋白实验揭示其调控细胞迁移和侵袭的机制，提出靶向ETB受体可能成为癌症治疗策略。
3. **《Functional characterization of endothelin receptors in vascular smooth muscle using recombinant proteins》**
- **作者**: Masaki T, Yanagisawa M.
- **摘要**: 利用重组ETB受体蛋白研究其在血管平滑肌细胞中的功能，发现ETB激活后通过钙离子通道调控血管收缩，并分析其与ETA受体的信号通路差异。
**提示**：以上文献为示例，实际引用时建议通过PubMed或Google Scholar检索最新研究，并核对作者及年份准确性。
**Background of ETB Recombinant Protein**
The endothelin type B (ETB) receptor, a G protein-coupled receptor (GPCR), plays a critical role in the endothelin system, which regulates vascular tone, cell proliferation, and tissue remodeling. Endothelins (ET-1. ET-2. ET-3) are potent vasoactive peptides that bind to two receptor subtypes: ETA and ETB. While ETA primarily mediates vasoconstriction and smooth muscle cell growth, ETB exhibits dual roles depending on its localization. Endothelial ETB receptors promote vasodilation by stimulating nitric oxide and prostacyclin release, whereas smooth muscle ETB receptors contribute to vasoconstriction and fibrosis. Dysregulation of ETB signaling is implicated in cardiovascular diseases, pulmonary hypertension, and cancer.
Recombinant ETB protein, engineered via heterologous expression systems (e.g., mammalian, insect, or bacterial cells), serves as a vital tool for studying ETB-specific functions and drug discovery. Its production involves cloning the ETB gene into expression vectors, followed by purification using affinity chromatography. The recombinant protein retains ligand-binding capacity and downstream signaling properties, enabling *in vitro* assays to screen ETB-targeted therapeutics or probe signaling pathways.
ETB recombinant protein is particularly valuable in dissecting its role in diseases. For instance, in pulmonary arterial hypertension (PAH), ETB dysfunction exacerbates vascular remodeling, making it a therapeutic target. Additionally, ETB’s involvement in cancer progression, such as melanoma and glioblastoma, underscores its relevance in oncology research. By enabling structural studies (e.g., crystallography) and functional analyses, recombinant ETB protein accelerates the development of selective antagonists or agonists, offering potential treatments for ETB-associated disorders. Its application extends to diagnostic assays and biomarker research, highlighting its multifaceted importance in biomedical sciences.
×
